Radioimmunotherapy in Oncology

Journal Article · Fri Dec 15 04:00:00 EST 2017 · Current Radiology Reports

DOI:https://doi.org/10.1007/S40134-017-0258-0· OSTI ID:22876218

Ryan, Davinia; Bodei, Lisa ^[1]

---

1. Memorial Sloan Kettering Cancer Center, Department of Radiology, Molecular Imaging and Therapy Service (United States)

Purpose of Review: Radioimmunotherapy (RIT) is the targeting of radiosensitive tumors through the use of monoclonal antibodies. The purpose of this review is to discuss the benefit and challenges of RIT. We appraise factors that determine optimal targeting of tumor such as choice of target, targeting antibody, and the associated radionuclide, as well as the current methods to potentiate RIT effect. Recent Findings: Radioimmunotherapy has a well-established role in the treatment of hematological malignancies. Recent completed and current studies in the treatment of solid malignancies are however demonstrating good clinical response with acceptable toxicity profiles. Summary: Since its inception, improved molecular engineering and targeting of new molecules, the discovery of new potential tumor targets, and the incorporation of methods to potentiate effect and reduce toxicity, will probably see radioimmunotherapy becoming a more commonplace treatment in the management of both hematological and solid malignancies.

• OSTI ID: 22876218
• Journal Information: Current Radiology Reports, Journal Name: Current Radiology Reports Journal Issue: 12 Vol. 5; ISSN 2167-4825
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
LYMPHOMAS
MONOCLONAL ANTIBODIES
RADIOIMMUNOTHERAPY
RADIOISOTOPES